Abstract
Disputes still arise about the adverse effect of perioperative transfusion on survival of patients with malignant solid tumors. In order to find some answers to these controversies the author has studied 880 new patients with operable breast cancer, among whom 486 (55.2%) had received perioperative transfusion. In 86% of the patients the tumor size, when known, measured 3.0 cm (T2) or less. In general the ten-year actuarial survival of the 486 transfused patients has been 59.9% versus 66.7% for 394 nontransfused ones, X2 = 4.47; d.o.f. = 1, P <0.05. In multivariate analysis it was noted that only positive nodes had affected the survival significantly (P = 10-9) and blood group had produced a trend (P = 0.08). However, when the period cohort was eliminated, the adverse effect of transfusion became evident in patients with blood group A in the 1968-69 and 1970-71 cohorts but not in those with blood group O. It is concluded that the combined effect of transfusion and blood group, as a risk factor, is not as strong as positive nodes and large size of tumor. This study confirms that transfusion effect, at surgery, is a blood-group-related phenomenon.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
